One year results of anti-VEGF treatment in pigment epithelial detachment secondary to macular degeneration

Abstract

Purpose: Pigment epithelial detachment (PED) may be seen in all stages of agerelated macular degeneration (ARMD) and may lead to poor prognosis. In this study, we retrospectively examined the effect of anti-VEGF treatments in ARMD patients with vascularized PED. Methods: Medical records of 15 patients with PED secondary to ARMD were re viewed retrospectively. The diagnosis of PED was made with fundoscopy, fundus fluorescein angiography and optical coherence tomography. Patients were treated with intravitreal ranibizumab or/and bevacizumab and followed up for a minimum of one year. PED height and best corrected visual acuity (BCVA) was obtained before the first intravitreal anti-VEGF injection and again at the 1 st , 3 rd , 6 th and 12 th month after the injection. Results: The mean baseline BCVA was 0.71 ± 0.48 logarithm of the minimal angle of resolution (logMAR) unit and the mean baseline PED height was 361 ± 153 µ. The mean injection count per eye was 3.9 ± 2.9. There was a significant reduce in mean PED height (247 ± 177 µ) also in 2 eyes PED completely resolved at the end of the follow up period. The mean BCVA at 12 th month (0,69 ± 0,37) were not different from the baseline record. Conclusions: This retrospective case series showed that intravitreal anti-VEGF therapy preserved vision and reduced PED height in PED patients in a one-year follow-up period.

Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration

“…These findings are consistent with prior reports 3–7. Yuksel et al 6 demonstrated that the improved effects of fvPED height changes were most apparent at 1 month and remained stable through 1 year. Bolz et al 8 reported that this therapeutic effect was seen at 1 week suggesting that the beneficial effects of anti-VEGF therapies on fvPED height occur quickly after treatment initiation.…”

One-Year Results of Aflibercept in Vascularized Pigment Epithelium Detachment due to Neovascular AMD: A Prospective Study

“…Larger clinical trials for the treatment of nAMD have either excluded eyes with PEDs or, if included, have not performed subanalysis of the PED's response to treatment (4–5–6–7–8–9–10–11–12–13–14–15), so there is limited evidence for the efficacy of anti-vascular endothelial growth factor (VEGF) agents for the treatment of PED from large cohorts. A range of case reports and smaller, mainly retrospective, studies have evaluated the response of PEDs to pegaptanib (a selective anti-VEGF agent), bevacizumab, and ranibizumab (nonselective anti-VEGF agents) in eyes with nAMD (16–17–18–19–20–21); however, the outcomes are conflicting and provide no clear guidance for the use of this class of therapy in the treatment of PED.…”

Volumetric Analysis of Vascularized Serous Pigment Epithelial Detachment Progression in Neovascular Age-Related Macular Degeneration Using Optical Coherence Tomography Angiography

“…V ascularized pigment epithelial detachment (PED) is a common variant of neovascular age-related macular degeneration (AMD) and is most often associated with type 1 neovascularization (NV) previously referred to as occult choroidal neovascularization (CNV). [1][2][3][4][5][6][7][8][9][10][11] Pigment epithelial detachments can assume various morphologic configurations, and a number of different terms have been used to describe PED formation in neovascular AMD, including fibrovascular PED, vascularized serous PED (vsPED), and more recently multilayered PED. 3,[12][13][14] Type 1 NV accounts for up to 40% to 50% of newly diagnosed treatment-naïve patients with exuda-tive AMD.…”